Lokavant’s AI-Powered Platform Slashes Clinical Trial Modeling Time from Weeks to Minutes
New York, USA — April 23, 2025 — In a pivotal move to modernize drug development operations, Lokavant, a clinical intelligence company spun out from Roivant Sciences, has launched Spectrum v1.5, an AI-driven platform designed to streamline clinical trial feasibility modeling. The tool reduces project planning timelines from five weeks to under five minutes, representing a breakthrough in clinical trial optimization.
The stakes are high in pharmaceutical R&D, where each day of trial delay can cost sponsors approximately $40,000, and even more for blockbuster therapies. Nearly 80% of clinical trials fail to meet their enrollment deadlines, according to Biopharma Dive, contributing to multi-billion-dollar losses annually.
Next-Gen Feasibility with Causal AI at the Core
What differentiates Spectrum v1.5 from conventional feasibility tools is its use of causal AI — a subset of artificial intelligence that moves beyond correlation to uncover why enrollment trends occur. Unlike static feasibility reports that rely on fragmented historical datasets, Lokavant’s platform draws from a dynamic repository of over 500,000 global trial records, offering:
- Hyper-granular scenario modeling across countries, regions, and sites
- Adaptive trial forecasting based on real-time study data
- Predictive enrollment simulations for diverse protocol designs
- Screening volume analysis to align recruitment efforts with study goals
“This isn’t just operational efficiency. It’s strategic foresight,” said Jonathan Crowther, Head of Predictive Analytics at Pfizer. “We now have the ability to pivot faster, forecast smarter, and build more resilient trials.”
Why Causal AI Matters in Clinical Research
While most AI platforms identify patterns, causal AI goes a level deeper, uncovering root causes such as protocol design flaws, site-level recruitment barriers, or population misalignment. This allows pharmaceutical sponsors and Contract Research Organizations (CROs) to pinpoint modifiable factors influencing dropout rates, screen failures, and low patient engagement.
“Quantifying uncertainty while pinpointing reliable enrollment drivers is the future,” noted Rohit Nambisan, CEO and co-founder of Lokavant. “Causal AI gives us the power to make data-driven decisions that reflect not just historical trends, but actual study dynamics.”
Real-World Impact and Strategic Partnerships
Spectrum v1.5 is already being piloted by major industry players including Pfizer, Novartis, and IQVIA, as part of their digital transformation roadmaps. The platform integrates seamlessly with electronic data capture (EDC) tools and clinical trial management systems (CTMS) such as Medidata, Oracle Health Sciences, and Veeva Systems.
Early adopters report:
- 65% reduction in site selection cycle time
- 30% improvement in enrollment target accuracy
- Enhanced mid-study corrections through continuous reforecasting
A Competitive Edge in the AI-for-Trials Market
Lokavant joins a crowded but rapidly growing space of clinical AI startups, competing with platforms like:
- Antidote Technologies (UK) – Patient matching and recruitment analytics
- Deep 6 AI (US) – EMR-based patient feasibility analysis
- Unlearn.AI – Synthetic control arms for accelerated trials
- Saama Technologies – AI-powered analytics across clinical operations
However, Lokavant’s niche focus on causal inference and adaptive forecasting gives it a unique positioning — especially amid the increasing complexity of oncology, rare disease, and decentralized trial designs.
Market Outlook
The clinical trial software market is projected to surpass $7.5 billion by 2030, driven by the increasing adoption of AI, real-world data integration, and pressure to speed up time-to-market for therapeutics. Lokavant’s launch of Spectrum v1.5 aligns with the global shift toward digitally enabled, patient-centric trials.
Final Thoughts
As regulatory bodies like the FDA and EMA push for more agile, transparent trial processes, platforms like Lokavant Spectrum v1.5 are paving the way for faster, smarter, and more adaptive drug development. By harnessing AI to eliminate inefficiencies in trial planning, Lokavant is not just accelerating timelines — it’s redefining what’s possible in clinical innovation.
Leave a comment